AXSOME THERAPEUTICS, INC. Payments of Debt Issuance Costs
AXSOME THERAPEUTICS, INC. (AXSM) reported Payments of Debt Issuance Costs of $3.64 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-23.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfDebtIssuanceCosts · last filed 2026-08-10
- AXSOME THERAPEUTICS, INC. payments of debt issuance costs for the quarter ending 2025-12-31 was $0.00.
- AXSOME THERAPEUTICS, INC. payments of debt issuance costs for the quarter ending 2025-09-30 was $0.00.
- AXSOME THERAPEUTICS, INC. payments of debt issuance costs for the quarter ending 2023-12-31 was -$855.00K.
- AXSOME THERAPEUTICS, INC. payments of debt issuance costs for the quarter ending 2023-09-30 was $856.00K.
- AXSOME THERAPEUTICS, INC. payments of debt issuance costs for fiscal 2025 was $3.64M.
- AXSOME THERAPEUTICS, INC. payments of debt issuance costs for fiscal 2023 was $1.44M, a 196.10% increase from fiscal 2022.
- AXSOME THERAPEUTICS, INC. payments of debt issuance costs for fiscal 2022 was $487.00K, a 57.61% increase from fiscal 2021.
- AXSOME THERAPEUTICS, INC. payments of debt issuance costs for fiscal 2021 was $309.00K, a 71.98% decline from fiscal 2020.
| Period end | Payments of Debt Issuance Costs 3 month | Payments of Debt Issuance Costs 6 month | Payments of Debt Issuance Costs 6 month as first filed | Payments of Debt Issuance Costs 9 month | Payments of Debt Issuance Costs 9 month as first filed | Payments of Debt Issuance Costs 12 month | Payments of Debt Issuance Costs 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $0.00 derived: sum of 2 quarters · filed 2026-02-23 | $3.64M 10-K · filed 2026-02-23 | ||||
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $3.64M 10-Q · filed 2025-11-03 | |||||
| 2025-06-30 | $3.64M 10-Q · filed 2026-08-10 | ||||||
| 2023-12-31 | -$855.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $1.00K derived: sum of 2 quarters · filed 2026-02-23 | $225.00K derived: sum of 3 quarters · filed 2026-02-23 | $1.44M 10-K · filed 2026-02-23 | |||
| 2023-09-30 | $856.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $1.08M derived: sum of 2 quarters · filed 2024-11-12 | $2.30M 10-Q · filed 2024-11-12 | $2.30M derived: sum of 4 quarters · filed 2025-02-18 | |||
| 2023-06-30 | $224.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | $1.44M 10-Q · filed 2024-08-05 | $1.44M derived: sum of 3 quarters · filed 2025-02-18 | $1.44M derived: sum of 4 quarters · filed 2025-02-18 | |||
| 2023-03-31 | $1.22M 10-Q · filed 2024-05-06 | $1.22M derived: sum of 2 quarters · filed 2025-02-18 | $1.22M derived: sum of 3 quarters · filed 2025-02-18 | ||||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-18 | $0.00 derived: sum of 2 quarters · filed 2025-02-18 | $487.00K 10-K · filed 2025-02-18 | $487.16K 10-K · filed 2023-02-28 | |||
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $487.00K 10-Q · filed 2023-11-06 | $487.16K 10-Q · filed 2022-11-07 | ||||
| 2022-06-30 | $487.00K 10-Q · filed 2023-08-07 | $487.16K 10-Q · filed 2022-08-09 | |||||
| 2021-12-31 | $309.00K 10-K · filed 2024-02-23 | $309.34K 10-K · filed 2023-02-28 | |||||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $1.10M 10-K · filed 2023-02-28 | |||||
| 2020-09-30 | $1.10M 10-Q · filed 2020-11-05 | ||||||
| 2018-12-31 | $26.00K 10-K · filed 2021-03-01 | ||||||
| 2016-12-31 | $64.93K 10-K · filed 2019-03-15 | ||||||
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-07 | $0.00 derived: sum of 2 quarters · filed 2018-03-07 | $12.49K 10-K · filed 2018-03-07 | ||||
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-14 | $12.49K 10-Q · filed 2016-11-14 | |||||
| 2015-06-30 | $12.49K 10-Q · filed 2016-08-09 | ||||||
| 2014-12-31 | $25.00K 10-K · filed 2017-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |